En Es
Categories

Industry News


Nova Biomedical Launches New BioProfile FLEX2 On-Line Autosampler

By Labmedica International staff writers
03 Jan 2020

Image: BioProfile FLEX2 On-Line Autosampler (Photo courtesy of Nova Biomedical)Nova Biomedical (Waltham, MA, USA) has launched the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to three weeks of walkaway, automated sampling, analysis, and feedback control of key cell culture analytes. The FLEX2 measures up to 16 tests, including pH, gases, metabolites, osmolality, cell density, and cell viability.

Nova develops and manufactures state-of-the-art, whole blood point-of-care and critical care analyzers, as well as the most advanced instruments for cell culture monitoring in the biotechnology market. Nova’s biosensor technology is incorporated in its products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers for the rapid measurement of over 20 analytes. Nova’s biotechnology-specific BioProfile line has pioneered comprehensive cell culture testing, providing over 16 critical cell culture tests with 12 unique instrument offerings for a broad range of cell culture applications.

Nova’s FLEX2 combines its MicroSensor Card chemistry technology with optical measurements and freezing point osmometry to offer an automated and comprehensive cell culture analyzer that eliminates chemistry sensor maintenance, increases analyzer speed, and reduces sample volume. With the OLS, FLEX2 uses a small sample volume of 5.6 mL for the 16-test assay to allow frequent sampling for this detailed look at culture performance. Up to 24 samples per day for each of 10 bioreactors can be analyzed in as fast as six minutes, with proven comparability to manual sampling. The OLS provides automated sampling, analysis, and feedback control of 10 bioreactors in as fast as one hour for chemistry results, with only 20 minutes needed for setup. The ability of OLS and FLEX2 to provide unaided capture of key cell culture attributes across 10 bioreactors saves hours of scientists’ time versus manual sampling and analysis, and eliminates after-hours cell culture monitoring.

“We are excited to launch the next addition to the BioProfile FLEX2 platform with the On-Line Autosampler. FLEX2 OLS represents the latest in cell culture automation technology and further demonstrates Nova’s leadership and history of innovation,” said Matt McRae, sales product line manager at Nova.

Related Links:
Nova Biomedical



E-mail Print
FaceBook Twitter Google+ Linked in

Nova Biomedical

Nova is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers. Nova’s biosensor technology is incorporated into products ranging from handheld meters for self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes.
Gold member
More info

More articles about Nova Biomedical

25 Jan 2021
Nova Biomedical Adds Sample Retain Collector to BioProfile FLEX2 Cell Culture Analyzer
Nova Biomedical (Waltham, MA, USA) has added a Sample Retain Collector (SRC) for its BioProfile FLEX2 automated cell culture analyzer which measures up to 16 tests including pH, gases, metabolites, osmolality, cell density, and cell viability.
Read More
19 Nov 2020
Nova Biomedical Launches New Laboratory Blood Glucose Reference Analyzer
Nova Biomedical (Waltham, MA, USA) has launched Nova Primary, a rapid, accurate, easy to use, blood glucose laboratory analyzer that fills the need for a new glucose reference analyzer to replace the YSI STAT PLUS 2300 Glucose and L-Lactate analyzer from YSI, Inc., (Yellow Springs, OH, USA).
Read More
20 Apr 2020
Nova's Stat EMS Basic Blood Testing System Launched in CE Mark Countries
Nova Biomedical (Waltham, MA, USA) has launched the Stat EMS Basic blood testing system for ambulance and emergency care in CE mark countries. Stat EMS Basic measures fingerstick capillary lactate, glucose, ketone, hemoglobin, and hematocrit in six to 40 seconds with laboratory-quality results.
Read More
20 Apr 2020
Nova's Stat Profile Prime Plus Blood Gas Analyzer Receives FDA Clearance for POC Use
Nova Biomedical (Waltham, MA, USA) has secured clearance from the US Food and Drug Administration (FDA) for its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care (POC) use.
Read More
08 Apr 2020
Nova Biomedical Adds PT/INR Test to Allegro Analyzer for POC Testing
Nova Biomedical (Waltham, MA, USA) has added PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. With the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the POC.
Read More

Additional news

18 Jan 2022
Global Coagulation Analyzers Market Driven by Growing Awareness About Timely Diagnosis of Blood Clots
The global coagulation analyzers market is expected to reach USD 11.7 billion by 2028, driven by the increasing understanding of blood clots and the fact that they can be avoided with early detection.
Read More
17 Jan 2022
Mobile C-Arms Market to Surpass USD 1.6 Billion in 2027 Due to Growing Preference for Minimally Invasive Surgeries
The global mobile C-arms market is expected to grow at a CAGR of 5.2% from USD 1.07 billion in 2019 to USD 1.61 billion in 2027, driven primarily by an increase in the global geriatric population, rising burden of chronic and acute diseases across the world, increasing volumes of orthopedic, cardiac, neurological, and oncological surgical procedures, and growing preference for minimally invasive surgeries.
Read More
14 Jan 2022
Medlab Middle East to Reveal Latest Innovations and Technologies in Mobile Labs for COVID-19 Testing
The latest technology and innovation in the global fight against COVID-19 and beyond will be on show at the next edition of Medlab Middle East when it returns to the Dubai World Trade Center from 24-27 January 2022 with mobile molecular testing and diagnosis stations, or ‘laboratories on wheels’, from companies such as Seegene, Inc. (Seoul, Korea) taking center stage.
Read More
13 Jan 2022
Global Coagulometers Market to Be Driven by Rising Prevalence of Blood Disorders
The global coagulometers market is being driven by a rise in the incidence and prevalence of blood disorders such as hemophilia that is fueling the demand for more diagnostic tools.
Read More
11 Jan 2022
Medlab Middle East to Return as Standalone Event in 2023
Informa Markets (London, UK), organizers of Medlab Middle East, have announced that the MENA region’s leading exhibition for the laboratory industry will return to a standalone event in 2023.
Read More
11 Jan 2022
J&J Medical Devices Companies Partners with Microsoft to Further Enable its Digital Surgery Solutions
The Johnson & Johnson Medical Devices Companies (JJMDC; New Brunswick, NJ, USA) will collaborate with Microsoft (Redmond, Wash., USA; www.microsoft.com) to further enable and expand JJMDC’s secure and compliant digital surgery ecosystem.
Read More
10 Jan 2022
ICU Medical Completes Acquisition of Smiths Medical to Create Leading Infusion Therapy Company
ICU Medical Inc. (San Clemente, CA, USA) has completed its acquisition of Smiths Medical (Minneapolis, MN, USA) from Smiths Group plc that includes syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical's existing businesses, the combined companies create a leading infusion therapy company.
Read More
05 Jan 2022
Global Portable Ultrasound Scanner Market to Be Driven by Rising Trauma and Accident Cases
The global portable ultrasound scanner market is being driven by an increase in targeted illnesses, rise in trauma & accident cases, surge in demand for less invasive operations, and the emergence of a senior population at a high risk of diseases.
Read More
04 Jan 2022
Global Mammography Workstations Market to Surpass USD 0.19 Billion in 2028 Due to Increasing Prevalence of Breast Cancer
The global mammography workstations market is projected to grow at a CAGR of 6.8% from about USD 0.12 billion in 2020 to more than USD 0.19 billion in 2028, led by increasing prevalence of breast cancer across the world, growing need for early breast cancer diagnosis and treatment, rise in government initiatives to spread breast cancer awareness, and rapid adoption of advanced mammography workstations in hospitals, clinics, and breast care centers.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions